The evaluation of SMA biomarkers in the above-mentioned reviews relied primarily on the clinical outcomes, including motor function, electrophysiological tests, and respiratory function, as well as some molecular markers, including quantification of the SMN mRNA or protein levels, plasma pNfH, and serum creatinine levels. Here, SMN2 is linked to proximal spinal muscular atrophy.